Navigation Links
Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market
Date:10/6/2010

acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

CAMBIA is not indicated for prophylactic therapy or for cluster headache.

Important Safety Information

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS NSAIDs, including CAMBIA, may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use or in patients with CV disease or risk factors for CV disease. CAMBIA is contraindicated for peri-operative pain in coronary artery bypass graft surgery. NSAIDs increase the risk of gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk.

Use the lowest effective dose for the shortest possible duration. Long-term administration of NSAIDs can result in serious and potentially fatal events, including CV thrombotic events or GI reactions.

CAMBIA is contraindicated in patients with hypersensitivity to diclofenac or other NSAIDs, and in patients with preexisting asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic-like reactions have been reported in such patients. Anaphylactic reactions may also occur in patients with the aspirin triad or in patients without prior exposure to CAMBIA. CAMBIA is contraindicated in patients with the aspirin triad. Discontinue immediately if an anaphylactic reaction occurs.

Renal papillary necrosis and other renal injury may occur with long-term use of NSAIDs. Use CAMBIA with caution in patients at risk, including the elderly, those taking diuretics or ACE inhibitors, those with renal impairment, heart failure, or liver impairment. CAMBIA is not recommended in patients with advance
'/>"/>

SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. US WorldMeds Acquires Solstice Neurosciences
2. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
3. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
4. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
5. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
6. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
7. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
8. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. DMC Sinai-Grace Selects Loopback Communications Readmission Reduction™ Services
11. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Corporation (Nasdaq: IRIX ) today announced that management ... 23rd Annual OC Growth Stock Conference on Monday, March 14, ... March 13-16 at the Ritz Carlton Laguna Niguel in Dana ... live webcast on the Investor section of IRIDEX,s website at: ...
... Medical Devices strengthened its executive team with the appointment ... Joseph Lee, Xeridiem Medical Devices, President said, "I am ... Medical Devices as Vice-President Business Development, effective March 1, ... design and development services with a focus on sales ...
Cached Medicine Technology:Xeridiem Medical Devices Appoints Renae Moomjian, Vice President, Business Development 2
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... The American Physical Therapy Association (APTA) is urging ... physical therapist, in light of a new federal survey ... nearly 12 percent of children use alternative medicine ... for treatment. Results of the 2007 survey of more ...
... 15, 2008 A program at Washington University School ... Hospital designed to increase awareness about sickle cell disease ... faith community led to a 60 percent increase in ... The program, called Sickle Cell Sabbath, was formally launched ...
... Statement , , VIRGINIA BEACH, ... AGP ) announced today that it filed a universal shelf ... Commission on December 15, 2008. The registration statement enables the ... debt, common stock, preferred stock and other securities at prices ...
... for Fighting AIDS joins PEPFAR, Nike Foundation, Coca-Cola Africa Foundation ... , NAIROBI, Kenya, Dec. 15 ... in Nairobi will rely on Rotarians for Fighting AIDS (RFFA) ... and economic development opportunities. , , ...
... Dec. 15 Streamline Health Solutions, Inc. (Nasdaq: STRM ) today announced ... 31, 2008. , , Highlights of the quarter and ... Revenues increased 11% versus comparable quarter in the previous ... 31, 2007 , Year-to-date company has won 8 ...
... of the American,Association of Drilling Engineers (AADE) recently ... to advance cancer research. The funds will,be used ... surgeon,Eugene Kim. The research program is focused on ... neuroblastoma, a deadly pediatric cancer. , ...
Cached Medicine News:Health News:Physical therapy offers evidence-based solution to musculoskeletal pain 2Health News:Church effort sharply increases first-time African-American blood donors 2Health News:AMERIGROUP Files Shelf Registration Statement 2Health News:Rotary Action Group Helps Launch Major Public-Private HIV Prevention Initiative in Kenya 2Health News:Rotary Action Group Helps Launch Major Public-Private HIV Prevention Initiative in Kenya 3Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 2Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 3Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 4Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 5Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 6Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 7Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 8Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 9Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 10Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 11Health News:Drilling Engineers Donate $35,000 to Texas Children's Hospital 2
ApolipoproteinA-1 & B Calibrator...
CRP Calibrator...
Fructosamine controls level 3...
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Medicine Products: